Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations

19 September 2019 - After a methodological uncertainty has been resolved, analyses on overall survival are now usable ...

Read more →

Germany may have the answer for reducing drug prices

11 September 2019 - American lawmakers attempting to stem spiraling drug costs might find inspiration in Germany, where the government’s ...

Read more →

Dacomitinib in advanced lung cancer: variety of disadvantages lifts survival advantage

 1 August 2019 - Prolonged survival is sometimes accompanied by severe side effects, symptom and quality of life deterioration ...

Read more →

Ezetimibe reduces the risk of heart attacks and strokes

26 July 2019 - Added to existing statin therapy, ezetimibe is preventative in patients with CHD and acute coronary syndrome. ...

Read more →

Early benefit assessment reveals weaknesses in the development of new drugs

11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...

Read more →

New drugs: where did we go wrong and what can we do better?

10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...

Read more →

Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods

10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...

Read more →

Negotiating drug prices without restricting patient access: lessons from Germany

27 June 2019 - In the ongoing conversation about high drug prices in the United States, some loud voices argue ...

Read more →

German patients get the latest drugs for just $11. Can such a model work in the U.S.?

19 June 2019 - Patients who come to the Havelhöhe cancer clinic in the leafy outskirts of Germany’s capital are ...

Read more →

UK, Germany, dissociate from WHO drug pricing resolution

8 June 2019 - The passage of a landmark resolution on improving the transparency of markets for medicines at the latest ...

Read more →

Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma

15 May 2019 - There are no serious disadvantages in terms of overall survival. ...

Read more →

Apalutamide in prostate cancer: indication of significant added benefit

2 May 2019 - Study shows significant slowing of symptomatic progression. ...

Read more →

Ribociclib in advanced breast cancer: survival benefits, but also severe side effects

15 April 2019 - In the overall view, an added benefit is not proven. ...

Read more →

Numerous G-BA decisions on new medicines - five active substances with considerable added value

22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the ...

Read more →

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →